Nasdaq
360Dx Index Declines 4 Percent in February, Ending Streak of Gains
Of the 32 companies in the index, 14 firms saw their stock prices increase, while 18 saw their share prices decline.
Infectious Disease Dx Firm Talis Biomedical Raises $254M in IPO
The firm offered 15,870,000 shares of its common stock, including 2,070,000 shares sold pursuant to the full exercise of the underwriters' option.
Interpace Biosciences Receives Nasdaq Delisting Notice, Initiates Restructuring
The notice was issued due to the company's extended period of non-compliance with the minimum $2.5 million stockholder's equity requirement for continued listing.
Fulgent Genetics, Genetron Pace Stock Price Increases as 360Dx Index Rises 10 Percent to Start 2021
Of the 32 companies in the index, 27 firms saw their stock prices increase, while 5 saw their share prices decline.
Lucira Health Files for $115M IPO
The company, which is developing instrument-free, low-cost molecular diagnostics platform for infectious disease testing, plans to float its shares on the Nasdaq.
Jun 19, 2020
Genetron Health Prices $256M US IPO
Jun 16, 2020
Progenity Eyes $122.6M in Amended IPO
Jun 15, 2020
Genetron Health Targeting $175.5M in Amended US IPO
Apr 9, 2020